Co-Authors
This is a "connection" page, showing publications co-authored by Maria Gavriatopoulou and Efstathios Kastritis.
Connection Strength
5.013
-
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
Score: 0.239
-
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. Hemasphere. 2021 Aug; 5(8):e614.
Score: 0.239
-
Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
Score: 0.228
-
Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
Score: 0.224
-
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circ Res. 2019 09 27; 125(8):744-758.
Score: 0.209
-
A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 11; 33(11):2654-2661.
Score: 0.206
-
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
Score: 0.201
-
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
Score: 0.201
-
How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 07; 9(96):36824-36825.
Score: 0.200
-
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 09; 32(9):1883-1898.
Score: 0.194
-
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
Score: 0.192
-
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018 04 05; 131(14):1568-1575.
Score: 0.188
-
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
Score: 0.186
-
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
Score: 0.180
-
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. Am J Hematol. 2017 Jul; 92(7):632-639.
Score: 0.179
-
Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017 Feb 28; 1(7):449-454.
Score: 0.177
-
Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
Score: 0.176
-
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
Score: 0.175
-
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. Expert Opin Investig Drugs. 2017 Feb; 26(2):197-205.
Score: 0.175
-
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
Score: 0.154
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.060
-
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
Score: 0.060
-
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
Score: 0.060
-
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
Score: 0.060
-
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
Score: 0.059
-
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
Score: 0.058
-
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers (Basel). 2021 Feb 12; 13(4).
Score: 0.058
-
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
Score: 0.058
-
Response of an oncology unit in the midst of the COVID-19 outbreak. J Oncol Pharm Pract. 2020 Dec; 26(8):1947-1952.
Score: 0.057
-
Screening for Gaucher disease among patients with plasma cell dyscrasias. Leuk Lymphoma. 2021 03; 62(3):761-763.
Score: 0.053
-
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
Score: 0.051
-
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
Score: 0.051
-
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
Score: 0.050
-
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018 11 07; 8(11):102.
Score: 0.050
-
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
Score: 0.048
-
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
Score: 0.048
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 03 09; 8(3):31.
Score: 0.047
-
Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
Score: 0.047
-
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
Score: 0.045
-
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Ann Hematol. 2017 Oct; 96(10):1707-1714.
Score: 0.045
-
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
Score: 0.026